GGrantIndex
← Leaderboards

Twinstrand Biosciences, Inc.

Seattle, WA

Compare ↔
$9,679,058
Total funding
3
Grants

Funding over time

peak $2M · FY2017–25
$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,679,058 · 3

By mechanism

R44$9,679,058 · 3

Investigators at Twinstrand Biosciences, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Kellie Bickel$2,555,3831 gr2Christopher S Hourigan$569,5521 gr

Emerging Leaders

6–10 yrs in

1Lindsey N Williams$1,036,7611 gr

All-Time

Most funded here, all years

1Kellie Bickel$2,555,3831 gr2Lindsey N Williams$1,036,7611 gr3Christopher S Hourigan$569,5521 gr

Largest grants

Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$1,985,831
R44 · FY2025 · CA
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$1,139,103
R44 · FY2023 · CA
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing$954,260
R44 · FY2019 · CA
Development of a Genotoxicity Assay using Duplex Sequencing$874,368
R44 · FY2020 · ES
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$859,730
R44 · FY2021 · CA
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing$823,853
R44 · FY2018 · CA
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$690,175
R44 · FY2019 · CA
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$690,175
R44 · FY2020 · CA
Development of a Genotoxicity Assay using Duplex Sequencing$619,680
R44 · FY2021 · ES
Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing$299,790
R44 · FY2018 · CA
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing$295,409
R44 · FY2017 · CA
Development of a Genotoxicity Assay using Duplex Sequencing$224,797
R44 · FY2019 · ES
Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing$221,887
R44 · FY2020 · CA